Disclaimer: The Foundation does not offer medical advice (more details)
Leiomyosarcoma (LMS) is a rare, aggressive cancer that arises in the body’s smooth muscle cells [1]. Uterine LMS (uLMS) develops in the uterus and accounts for fewer than 5% of uterine malignancies [2][3][4]. In the United States, it occurs roughly at a rate of 6 cases per million women per year [5][6][7].
We focus on a subset of LMS cases with a specific genetic alteration, called a PLAG1 fusion [8][9][10][11]. PLAG1 is a transcription factor, and it plays a crucial role in regulating gene expression. Recent studies have found PLAG1 fusions in myxoid uLMS and many other sarcomas.
We believe that the shared genetic feature may reveal potential vulnerabilities that offer a way to develop more effective therapies against this subtype of LMS.
